Zinger Key Points
- CEO Andres Fajardo highlights the commercial momentum in core target markets such as Brazil, Australia and Israel.
- Despite a decrease in revenue, the company achieves a higher gross margin.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Global medicinal cannabis company Clever Leaves Holdings Inc. CLVR CLVRW reported late Thursday its financial and operating results for the first quarter of 2023.
CEO Andres Fajardo highlighted the continued commercial momentum in core target markets such as Brazil, Australia and Israel, as well as the ramping up of Colombian smokable dry flower exports.
Gross Margin And Net Loss Show Remarkable Improvement
By implementing cost reduction measures, Clever Leaves has improved its financial performance in the first quarter of 2023.
Despite a decrease in revenue, the company achieved a higher gross margin and significantly reduced operating expenses, resulting in a substantial decrease in net loss.
Clever Leaves Highlights
- Revenue in the first quarter of 2023 was $4.0 million, compared to $5.0 million in the same period last year.
- Cannabinoid revenue decreased from $1.8 million to $1.2 million, while non-cannabinoid revenue also decreased to $2.8 million.
- Clever Leaves achieved a 480 basis point increase in gross margin, reaching 56.2%.
- The company's cost reduction measures led to a 48% year-over-year decrease in operating expenses and a net loss reduction of nearly 75%.
- Adjusted EBITDA loss improved by 35%, highlighting the benefits of restructuring and cost reduction initiatives.
- Clever Leaves reaffirmed its 2023 outlook, projecting revenue between $19 million and $22 million, with an adjusted gross margin between 58% and 63%.
- The company expects its adjusted EBITDA to range between $(13.6) million and $(10.6) million, representing a significant improvement compared to the previous year.
- Capital expenditures are estimated to decrease by 50% compared to 2022.
- Clever signed partnerships with leading pharmaceutical and cannabis companies, further strengthening its presence in key geographies.
Photo: Steve Buissinne on Pixabay.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!